위 정맥류 출혈에 대한 내시경적 정맥류 폐색술, 내시경적 정맥류 결찰술, 역행성 경정맥 위정맥류 폐색술 간의 치료효과 비교
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민슬기 | - |
dc.contributor.author | 김상균 | - |
dc.contributor.author | 김영석 | - |
dc.contributor.author | 배준용 | - |
dc.contributor.author | 이종찬 | - |
dc.contributor.author | 이세환 | - |
dc.contributor.author | 김홍수 | - |
dc.contributor.author | 정승원 | - |
dc.contributor.author | 장재영 | - |
dc.contributor.author | 문종호 | - |
dc.contributor.author | 이문성 | - |
dc.contributor.author | 김부성 | - |
dc.date.accessioned | 2021-08-12T06:45:03Z | - |
dc.date.available | 2021-08-12T06:45:03Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/17192 | - |
dc.description.abstract | Background/Aims: Endoscopic variceal obliteration (EVO), endoscopic variceal ligation (EVL), and balloon-occluded retrograde transvenous obliteration (BRTO) are used to manage gastric variceal bleeding. We compared the re-bleeding rates and survival times of these modalities. Methods: The study enrolled 103 patients with suspected gastric variceal bleeding between July 2001 and May 2009. For the management of gastric variceal bleeding, 52 patients underwent EVO; 36, EVL; and 15, BRTO. We evaluated their laboratory results and vital signs, and calculated the Child score, Child classification, and Model for End-stage Liver Disease score. Rebleeding was defined as new-onset hematemesis, hematochezia, melena, or endoscopically proven bleeding. Time-to-rebleeding and survival time were examined by Kaplan-Meyer analysis. A value of p<0.05 indicated statistical significance. Results: There were no significant differences in baseline characteristics among the three groups. The overall follow-up period averaged 65.13 months. During follow-up, rebleeding occurred in 17 patients (11 EVO, 5 EVL, and 1 BRTO). The times-to-rebleeding were 63.59, 75.79, and 51.41 months for EVO, EVL, and BRTO, respectively, and did not differ significantly (p=0.515). The median survival times were 77.42, 70.14, and 42.79 months, respectively, and also were not different significantly (p=0.978). Conclusions: There were no significant differences in the time-to-rebleeding or survival time among EVO, EVL, and BRTO. Further prospective, large-scale studies are needed. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한소화기학회 | - |
dc.title | 위 정맥류 출혈에 대한 내시경적 정맥류 폐색술, 내시경적 정맥류 결찰술, 역행성 경정맥 위정맥류 폐색술 간의 치료효과 비교 | - |
dc.title.alternative | Comparison among Endoscopic Variceal Obliteration, Endoscopic Band Ligation, and Balloon-occluded Retrograde Transvenous Obliteration for Treatment of Gastric Variceal Bleeding | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | 대한소화기학회지, v.57, no.5, pp 302 - 308 | - |
dc.citation.title | 대한소화기학회지 | - |
dc.citation.volume | 57 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 302 | - |
dc.citation.endPage | 308 | - |
dc.identifier.kciid | ART001553431 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Esophageal and gastric varices | - |
dc.subject.keywordAuthor | Gastrointestinal hemorrhage | - |
dc.subject.keywordAuthor | Liver cirrhosis | - |
dc.subject.keywordAuthor | Treatment | - |
dc.subject.keywordAuthor | 식도위정맥류 | - |
dc.subject.keywordAuthor | 위장관출혈 | - |
dc.subject.keywordAuthor | 간경변 | - |
dc.subject.keywordAuthor | 치료 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.